We are live on ! Find out more
PA

Perceptive Advisors Portfolio holdings

AUM $6.66B
1-Year Est. Return 360.84%
This Fund
S&P 500
This Quarter Est. Return
+21.92%
1 Year Est. Return
+360.84%
3 Year Est. Return
+1,707.27%
5 Year Est. Return
+3,210.42%
10 Year Est. Return
+53,055.89%
AUM
$1.44B
AUM Growth
+$302M
Cap. Flow
+$191M
Cap. Flow %
13.26%
Top 10 Hldgs %
50.32%
Holding
229
New
57
Increased
37
Reduced
31
Closed
55

Top Buys

Rank Stock Value
1
NXTM
NxStage Medical Inc.
NXTM
+$24.7M
2
MDVN
MEDIVATION, INC.
MDVN
+$23.8M
3
GBT
Global Blood Therapeutics, Inc.
GBT
+$18.4M
4
STJ
St Jude Medical
STJ
+$16.6M
5
LJPC
La Jolla Pharmaceutical Company
LJPC
+$11.4M

Top Sells

Rank Stock Value
1
AGN
Allergan plc
AGN
+$41.5M
2
HUM icon
Humana
HUM
+$20.1M
3
FPRX
Five Prime Therapeutics, Inc.
FPRX
+$12.4M
4
BAX icon
Baxter International
BAX
+$9.04M
5
XLRN
Acceleron Pharma
XLRN
+$6.5M

Sector Composition

Rank Sector Weight
1 Healthcare 78.68%
2 Consumer Staples 0.52%
3 Consumer Discretionary 0.08%
4 Financials 0.04%
5 Industrials 0.04%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
SCMP
126
DELISTED
Sucampo Pharmaceuticals, Inc.
SCMP
$451K 0.03%
41,096
+40,337
+5,314% +$452K
THC icon
127
Tenet Healthcare
THC
$22.1B
$448K 0.03%
+16,200
New +$479K
ELV icon
128
Elevance Health
ELV
$87.3B
$447K 0.03%
3,400
-347
-9% -$47.5K
ISEE
129
DELISTED
IVERIC bio, Inc. Common Stock
ISEE
$416K 0.03%
+8,145
New +$405K
ENZ
130
DELISTED
Enzo Biochem, Inc.
ENZ
$401K 0.03%
+67,113
New +$372K
SCYX icon
131
SCYNEXIS
SCYX
$56.4M
$380K 0.03%
2,188
– –
STLA icon
132
Stellantis
STLA
$19.4B
$379K 0.03%
62,248
-311
-0.5% -$2.25K
CNC icon
133
Centene
CNC
$32.3B
$353K 0.02%
9,896
– –
GRCE
134
Grace Therapeutics
GRCE
$45.2M
$336K 0.02%
4,928
– –
NTLA icon
135
Intellia Therapeutics
NTLA
$1.85B
$320K 0.02%
+15,000
New +$399K
CLDX icon
136
Celldex Therapeutics
CLDX
$3.19B
$312K 0.02%
+4,742
New +$301K
MACK
137
DELISTED
Merrimack Pharmaceuticals, Inc.
MACK
$270K 0.02%
6,355
– –
RACE icon
138
Ferrari
RACE
$72.6B
$254K 0.02%
6,200
– –
NVAX icon
139
Novavax
NVAX
$1.52B
$233K 0.02%
+1,600
New +$183K
VTRS icon
140
Viatris
VTRS
$19.4B
$216K 0.02%
+5,000
New +$221K
ONSIW
141
DELISTED
Oncobiologics, Inc. Series A Warrant Expiring 2/18/2019
ONSIW
$212K 0.01%
+462,500
New +$177K
ONSIZ
142
DELISTED
Oncobiologics, Inc. Series B Warrant
ONSIZ
$202K 0.01%
+462,500
New +$243K
STRR
143
DELISTED
Star Equity Holdings
STRR
$129K 0.01%
500
– –
ABT icon
144
Abbott
ABT
$197B
$120K 0.01%
+3,040
New +$121K
CDMO
145
DELISTED
Avid Bioservices, Inc. Common Stock
CDMO
$81K 0.01%
32,047
+28,571
+822% +$79.6K
IMGN
146
DELISTED
Immunogen Inc
IMGN
$79K 0.01%
+25,745
New +$161K
ABBV icon
147
AbbVie
ABBV
$465B
$77K 0.01%
+1,250
New +$76.2K
DPLO
148
DELISTED
DIPLOMAT PHARMACY, INC.
DPLO
$76K 0.01%
+2,175
New +$68.4K
HLF icon
149
Herbalife
HLF
$1.3B
$73K 0.01%
2,500
– –
ZLTQ
150
DELISTED
ZELTIQ Aesthetics, Inc.
ZLTQ
$72K 0.01%
2,638
-119,362
-98% -$3.36M
4 5
6
7 8

Similar funds

QP
Quilter Plc London, United Kingdom $6.65B AUM 37.83% 1-Year Est. Return
FCBT
First Citizens Bank & Trust Raleigh, North Carolina $6.69B AUM 24.48% 1-Year Est. Return
RWM
Ritholtz Wealth Management New York $6.7B AUM 32.7% 1-Year Est. Return
AWA
Arkadios Wealth Advisors Atlanta, Georgia $6.6B AUM 30.67% 1-Year Est. Return
WHRC
W.H. Reaves & Co Jersey City, New Jersey $6.59B AUM 31.9% 1-Year Est. Return
LSERS
Louisiana State Employees Retirement System Baton Rouge, Louisiana $6.74B AUM 53.06% 1-Year Est. Return
CAG
Crestwood Advisors Group Boston, Massachusetts $6.74B AUM 30.22% 1-Year Est. Return
MCM
Moore Capital Management New York $6.74B AUM 45.87% 1-Year Est. Return

Perceptive Advisors's Q2 2016 Portfolio in Review

As of Q2 2016, Perceptive Advisors held 229 positions worth $1.44B, up 27% from $1.14B the previous quarter. Its ten largest holdings account for 50% of the portfolio.

Perceptive Advisors deployed $191M of net new capital in Q2 2016, opening 57 new positions and adding to 37 existing holdings. Its largest new stake was NxStage Medical Inc.: 1,382,410 shares worth $30M.

By sector, the portfolio is most concentrated in Healthcare at 79% of assets, down from 93% a quarter earlier, followed by Consumer Staples and Consumer Discretionary.

On the sell side, the largest reduction was Five Prime Therapeutics, Inc., an estimated $12.4M trimmed.

  • Perceptive Advisors's largest Q2 2016 buy was NxStage Medical Inc.: 1,382,410 shares worth $30M.
  • Perceptive Advisors added most to MEDIVATION, INC. in Q2 2016, an estimated $23.8M increase.
  • Perceptive Advisors's biggest Q2 2016 reduction was Five Prime Therapeutics, Inc., cutting an estimated $12.4M.
  • Perceptive Advisors fully exited Allergan plc in Q2 2016, selling an estimated $41.5M.
  • Perceptive Advisors's ten largest holdings make up 50% of its $1.44B portfolio in Q2 2016.
  • Perceptive Advisors opened 57 new positions and closed 55 in Q2 2016.
  • Perceptive Advisors's portfolio value rose 27% quarter-over-quarter to $1.44B.

Based on Perceptive Advisors's 13F filing for Q2 2016, filed 11 Aug 2016.